ABOUT THIS EPISODE
In this episode of The Wellness Files, host Kari Beal sits down with obesity medicine specialist Dr. Christopher McGowan to discuss Retatrutide, the highly anticipated "triple agonist" weight loss drug currently in Phase 3 trials. They dive into its unprecedented weight loss potential, unique side effects like skin sensitivity, and the dangerous black market pathways patients are using to access it before FDA approval.
00:00 – Intro: The massive hype surrounding Retatrutide ("RETA")
01:58 – The dangers of seeking unapproved research drugs online
02:47 – Weight loss data: Reta's gastric bypass-level results vs. Wegovy https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
04:22 – How the "triple G" agonist works on three gut hormones
07:04 – The reality of muscle loss and preserving lean mass
08:41 – Side effects: Elevated heart rate and painful skin sensitivity
11:13 – Thyroid cancer warnings, pancreatitis, and contraindications
13:10 – Long-term safety: GLP-1 history vs. the new glucagon pathway
14:59 – Additional health benefits: Reversing fatty liver and joint pain
16:25 – The TikTok "Ratatouille" trend and black market peptide risks
19:47 – Projected FDA approval timeline and safe, legal alternatives
